



Supplemental Fig.1



S1. The phos-AKT(S473) in HeLa is higher than NIH3T3. This explains why GSK3 inhibitor treatment can't accumulate more TAZ protein level than control in HeLa cells. Because the high activity of AKT in HeLa inhibits GSK3 strongly, BIO treatment can only block TAZ degradation induced by LY294002 treatment but not elevate TAZ protein level than control.

Supplemental Fig.2



S2. TAZ degradation mutants stimulate cell migration. MCF10A cells expressing vector, TAZ, and TAZ^{S58/62A} were analyzed for migration by a wound healing assay.